| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA862: Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after trastuzumab and a taxane |
|
Medicine details |
|
| Medicine name | trastuzumab deruxtecan (Enhertu®) |
| Formulation | 100 mg powder for concentrate for solution for infusion |
| Reference number | 4781 |
| Indication | Treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received one or more prior anti HER2 based regimens |
| Company | Daiichi Sankyo UK Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 02/08/2022 |
| NICE guidance | |